loading
Precedente Chiudi:
$4.51
Aprire:
$4.51
Volume 24 ore:
46,507
Relative Volume:
0.19
Capitalizzazione di mercato:
$231.46M
Reddito:
$84.82M
Utile/perdita netta:
$-21.43M
Rapporto P/E:
-9.2959
EPS:
-0.49
Flusso di cassa netto:
$-27.23M
1 W Prestazione:
-11.23%
1M Prestazione:
-1.01%
6M Prestazione:
-41.84%
1 anno Prestazione:
-61.51%
Intervallo 1D:
Value
$4.40
$4.62
Intervallo di 1 settimana:
Value
$4.40
$5.24
Portata 52W:
Value
$3.55
$16.11

Y Mabs Therapeutics Inc Stock (YMAB) Company Profile

Name
Nome
Y Mabs Therapeutics Inc
Name
Telefono
646-885-8505
Name
Indirizzo
202 CARNEGIE CENTER, PRINCETON, NY
Name
Dipendente
107
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-04
Name
Ultimi documenti SEC
Name
YMAB's Discussions on Twitter

Confronta YMAB con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
YMAB
Y Mabs Therapeutics Inc
4.555 231.46M 84.82M -21.43M -27.23M -0.49
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.96 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
539.18 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.24 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
551.27 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.57 28.51B 3.81B -644.79M -669.77M -6.24

Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-22 Downgrade BofA Securities Neutral → Underperform
2024-11-18 Iniziato Oppenheimer Outperform
2024-08-16 Iniziato Cantor Fitzgerald Overweight
2024-06-28 Iniziato Truist Buy
2023-05-10 Aggiornamento Wedbush Neutral → Outperform
2023-04-03 Downgrade Guggenheim Buy → Neutral
2023-01-27 Downgrade Morgan Stanley Equal-Weight → Underweight
2023-01-05 Downgrade Cowen Outperform → Market Perform
2022-12-02 Downgrade BofA Securities Buy → Neutral
2022-10-31 Downgrade JP Morgan Neutral → Underweight
2022-10-31 Downgrade Wedbush Outperform → Neutral
2022-07-06 Ripresa Canaccord Genuity Buy
2022-06-24 Iniziato BMO Capital Markets Outperform
2022-02-03 Ripresa Guggenheim Buy
2021-11-19 Ripresa Morgan Stanley Equal-Weight
2021-11-16 Downgrade JP Morgan Overweight → Neutral
2021-05-07 Aggiornamento BofA Securities Neutral → Buy
2021-04-23 Ripresa Cowen Outperform
2021-03-22 Ripresa JP Morgan Overweight
2021-01-15 Downgrade BofA Securities Buy → Neutral
2020-11-09 Reiterato H.C. Wainwright Buy
2020-05-05 Iniziato Barclays Overweight
2020-05-01 Iniziato Janney Buy
2020-04-29 Iniziato Morgan Stanley Equal-Weight
2019-12-24 Iniziato JP Morgan Overweight
2019-11-20 Iniziato Guggenheim Buy
2019-09-04 Iniziato Wedbush Outperform
2019-04-01 Iniziato H.C. Wainwright Buy
2018-10-16 Iniziato BTIG Research Buy
2018-10-16 Iniziato BofA/Merrill Buy
Mostra tutto

Y Mabs Therapeutics Inc Borsa (YMAB) Ultime notizie

pulisher
Jun 15, 2025

Cantor Fitzgerald Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Overweight Recommendation - MSN

Jun 15, 2025
pulisher
Jun 13, 2025

Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles - Investing.com

Jun 13, 2025
pulisher
Jun 12, 2025

Millennium Management LLC Cuts Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 7,765 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

(YMAB) Long Term Investment Analysis - news.stocktradersdaily.com

Jun 11, 2025
pulisher
Jun 09, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DE - Defense World

Jun 08, 2025
pulisher
Jun 05, 2025

BNP Paribas Financial Markets Has $38,000 Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Jane Street Group LLC - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

YMAB CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Class Action Pending - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 02, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $179,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Deutsche Bank AG - Defense World

Jun 02, 2025
pulisher
May 30, 2025

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at Oppenheimer - Defense World

May 30, 2025
pulisher
May 29, 2025

Clear Street Reaffirms Their Buy Rating on Y-Mabs Therapeutics (YMAB) - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

How the (YMAB) price action is used to our Advantage - news.stocktradersdaily.com

May 29, 2025
pulisher
May 29, 2025

Oppenheimer Adjusts Target Price for Y-mAbs Therapeutics (YMAB) - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Y-mAbs Therapeutics (YMAB) Target Price Lowered by Oppenheimer | YMAB Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Oppenheimer Adjusts Price Target on Y-mAbs Therapeutics to $15 From $20, Maintains Outperform Rating - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Cautious Outlook on Y-Mabs Therapeutics Due to Delayed Milestones and Early-Stage Pipeline - TipRanks

May 29, 2025
pulisher
May 29, 2025

Y-mAbs Therapeutics’ (YMAB) “Outperform” Rating Reaffirmed at Wedbush - Defense World

May 29, 2025
pulisher
May 28, 2025

Transcript : Y-mAbs Therapeutics, Inc.Special Call - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Wedbush Lowers Price Target on Y-mAbs Therapeutics to $18 From $21, Maintains Outperform Rating - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Y-Mabs Therapeutics Updates on Radiopharmaceutical Progress - TipRanks

May 28, 2025
pulisher
May 28, 2025

Y-mAbs Therapeutics Announces Positive Phase 1 Trial Results for GD2-SADA in Metastatic Solid Tumors and Expands Radiopharmaceutical Pipeline - Nasdaq

May 28, 2025
pulisher
May 28, 2025

Clinical Trial Success: Y-mAbs Breakthrough in Cancer Treatment Shows Promise with Novel Radiopharmaceutical - Stock Titan

May 28, 2025
pulisher
May 27, 2025

Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025 - MSN

May 27, 2025
pulisher
May 26, 2025

Y-mAbs Therapeutics, Inc. Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - marketscreener.com

May 26, 2025
pulisher
May 26, 2025

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - The Manila Times

May 26, 2025
pulisher
May 26, 2025

Y-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research Meeting - Nasdaq

May 26, 2025
pulisher
May 26, 2025

Y-mAbs Advanced Cancer Trial Breakthrough: Key Data Coming for Revolutionary GD2-SADA Treatment - Stock Titan

May 26, 2025
pulisher
May 23, 2025

Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles - Investing.com Canada

May 23, 2025
pulisher
May 23, 2025

Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 22, 2025

What is HC Wainwright’s Forecast for YMAB FY2026 Earnings? - Defense World

May 22, 2025
pulisher
May 22, 2025

HC Wainwright Issues Pessimistic Estimate for YMAB Earnings - Defense World

May 22, 2025
pulisher
May 20, 2025

Caligan Partners LP Increases Stake in Y-mAbs Therapeutics Inc - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC Wainwright - Defense World

May 20, 2025
pulisher
May 19, 2025

What 7 Analyst Ratings Have To Say About Y-mAbs Therapeutics - Benzinga

May 19, 2025
pulisher
May 19, 2025

H.C. Wainwright Adjusts Price Target for Y-mAbs Therapeutics (YM - GuruFocus

May 19, 2025
pulisher
May 18, 2025

Price T Rowe Associates Inc. MD Cuts Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

May 18, 2025
pulisher
May 18, 2025

FY2025 EPS Estimates for YMAB Increased by Analyst - Defense World

May 18, 2025
pulisher
May 16, 2025

Formulation Is Key For Y-mAbs' Self-Assembling Antibody - Bioprocess Online

May 16, 2025
pulisher
May 16, 2025

Earnings Update: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st

May 16, 2025
pulisher
May 16, 2025

Oppenheimer Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World

May 16, 2025
pulisher
May 16, 2025

Q2 EPS Estimates for Y-mAbs Therapeutics Cut by Wedbush - Defense World

May 16, 2025
pulisher
May 15, 2025

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 15, 2025
pulisher
May 15, 2025

Y-mAbs Therapeutics’ Earnings Call: Mixed Sentiment and Future Outlook - TipRanks

May 15, 2025
pulisher
May 15, 2025

Y-mAbs Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Y-mAbs Therapeutics (YMAB) Maintains "Outperform" Rating, PT Low - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

May 15, 2025

Y Mabs Therapeutics Inc Azioni (YMAB) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Y Mabs Therapeutics Inc Azioni (YMAB) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Rossi Michael J
PRESIDENT & CEO
Mar 07 '25
Sale
5.20
3,917
20,368
137,083
Gad Thomas
CHIEF BUSINESS OFFICER
Mar 07 '25
Sale
5.23
10,810
56,536
202,721
$20.80
price up icon 0.77%
$35.76
price down icon 0.76%
$21.48
price up icon 0.96%
$98.46
price down icon 2.29%
$108.74
price up icon 2.15%
biotechnology ONC
$245.58
price up icon 1.50%
Capitalizzazione:     |  Volume (24 ore):